CAREERS
Three late-stage biotechnology firms—Triveni Bio, Ratio Therapeutics, and Basecamp Research—are actively expanding their scientific, clinical, and engineering headcounts after securing a combined $275 million in Series C financing during 2026. Backing clinical trials in immunology, targeted oncology radiopharmaceuticals, and AI-driven gene-editing platforms, the fresh capital is fueling active recruitment across Massachusetts, Utah, and London. For biopharma professionals navigating a selective job market, well-capitalized Series C companies offer near-term clinical momentum and commercial sca
As biopharma job seekers target resilient employers capable of weathering tighter venture markets, companies that have closed later-stage Series C financing stand out for their clinical validation and operational runway. Three high-growth biotechnology developers—Triveni Bio, Ratio Therapeutics, and Basecamp Research—raised a combined $275 million between June and September 2026 and are actively recruiting across research, clinical operations, manufacturing, and AI engineering.
1. Triveni Bio: $65 Million Series C Headquartered in Watertown, Massachusetts, Triveni Bio develops genetics-informed antibody therapies targeting primary disease drivers in immunological and inflammatory disorders such as atopic dermatitis, asthma, and eosinophilic esophagitis.
-
Pipeline & Clinical Momentum: Following its $65 million Series C raise in June 2026, Triveni completed enrollment in a Phase 2 proof-of-concept trial for its lead half-life extended monoclonal antibody, TRIV-509 (with topline data expected by year-end 2026), dosed its first Phase 2 patient for next-generation bispecific TRIV-573, and transferred pancreatitis candidate TRIV-920 to a rare-disease biopharma partner. CEO Vishal Patel was also named a finalist for the Ernst & Young Entrepreneur Of The Year 2026 award.
-
Open Roles: Recruiting in Watertown for positions including Senior Scientist (Clinical Pharmacology), Director of Medical Writing, and Senior Scientist (Translational Research).
2. Ratio Therapeutics: $70 Million Series C Boston-based Ratio Therapeutics engineers targeted radiopharmaceuticals for oncology using its proprietary Trillium and Macropa platforms, which harness alpha-emitting actinium-225 to selectively destroy tumor cells.
-
Pipeline & Pharma Partnerships: Backed by a $70 million Series C closed in July 2026, Ratio is advancing its lead candidate [Ac-225]RTX-2358 in the ATLAS Phase 1/2 trial for relapsed or treatment-resistant soft tissue sarcoma while scaling manufacturing capacity. The company also maintains strategic partnerships with Novartis (therapeutics) as well as Lantheus and Merck (diagnostics).
-
Open Roles: Hiring a Scientist/Senior Scientist (Radiopharma Development and Tech Transfer) and Facilities Engineer in West Valley City, Utah, alongside a Chemistry Laboratory Operations Associate in Boston.
3. Basecamp Research: $140 Million Series C Operating out of London with offices and laboratories in Cambridge, Massachusetts, Basecamp Research combines frontier biological AI models trained on proprietary biodiversity data with programmable DNA-writing technology.
- AI Foundation Models & Gene Insertion: Powered by its biological foundation model EDEN, Basecamp designs synthetic large serine recombinases (LSRs) capable of inserting healthy gene copies upstream of disease-causing mutations across oncology, autoimmunity, and diabetes. Its $140 million Series C closed in September 2026 will train next-generation EDEN models, advance AI-designed therapeutics toward the clinic, and expand pharma collaborations.
We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how." — Glen Gowers, Co-Founder & CEO, Basecamp Research
Open Roles: Recruiting for nearly a dozen roles across both hubs, including Senior Research Scientist (AI Safety and Biosecurity) in London, and Software Engineer (Science Platform) and Scientist (Peptide Discovery) in Boston.
People Matters · 8 hours ago
Anthropic Safeguards Researcher Tao Lin Warns Broadly Superhuman AI Could Arrive by Late 2027 and Make Humans Permanently Unemployable
Anthropic alignment and safeguards researcher Tao Lin has warned that "broadly superhuman AI"—systems matching or outperforming top human ex...
People Matters · 8 hours ago
Salesforce Layoffs 2026: India Employees Report Job Cuts With Garden Leave Extending Into February 2027
Cloud software giant Salesforce has initiated a fresh round of workforce reductions affecting employees in India and the United States, acco...
TechCentral.ie · 1 day ago
AI Hiring Demand Rises 10.6% in Ireland Even as Broader Tech Job Postings Fall 7.2%: Accenture Talent Tracker
Demand for artificial intelligence specialists in Ireland climbed 10.6% in the first half of 2026 to surpass 20,000 job postings, even as ov...
From MyDigiFolio
Reading about careers? Build yours.
One profile. Resume, vCard, portfolio, and email signatures — all generated in 3 minutes.
Build your page — free